



IFW16

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457D

DATE: 08/11/2004

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt  
 Output Set: N:\CRF4\08112004\I647457D.raw

3 <110> APPLICANT: Yeda Research and Development Company Ltd.  
 5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW  
 PEPTIDE  
 7 <130> FILE REFERENCE: 24390 (1276302)  
 9 <140> CURRENT APPLICATION NUMBER: 09/647,457D  
 C--> 10 <141> CURRENT FILING DATE: 2000-11-29  
 12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190  
 13 <151> PRIOR FILING DATE: 1999-09-29  
 15 <150> PRIOR APPLICATION NUMBER: 123925  
 16 <151> PRIOR FILING DATE: 1998-04-02  
 18 <160> NUMBER OF SEQ ID NOS: 15  
 20 <170> SOFTWARE: PatentIn version 3.2  
 22 <210> SEQ ID NO: 1  
 23 <211> LENGTH: 28  
 24 <212> TYPE: PRT  
 25 <213> ORGANISM: Unknown  
 27 <220> FEATURE:  
 28 <223> OTHER INFORMATION: being the immunologically active epitope  
 31 <220> FEATURE:  
 32 <221> NAME/KEY: MISC\_FEATURE  
 33 <222> LOCATION: (1)..(11) / /  
 34 <223> OTHER INFORMATION: Xaa(1) is S or absent; Xaa(2) is G or absent; Xaa(3) is E or  
 35 absent; Xaa(4) is T or absent; Xaa(5) is E or absent; Xaa(6) is  
 36 D or absent; Xaa(7) is T or absent; Xaa(8) is F or absent;  
 37 Xaa(9) is I or absent; Xaa(10) is A or absent; provided that  
 W--> 38 when Xaa(11) is absent, Xaa(1) through Xaa(10), inclusive, are  
 W--> 39 absent, and when Xaa(11) is D, Xaa(10) is A or absent; when  
 W--> 40 Xaa(10) is absent, Xaa(1) through Xaa(9), inclusive, are absent,  
 W--> 41 and when Xaa(10) is A, Xaa(9) is I or absent; when Xaa(9) is  
 W--> 42 absent, Xaa(1) through Xaa(8), inclusive, are absent, and when  
 W--> 43 Xaa(9) is I, Xaa(8) is F or absent; when Xaa(8) is absent,  
 W--> 44 Xaa(1) through Xaa(7), inclusive, are absent, and when Xaa(8) is  
 W--> 45 F, Xaa(1) through Xaa(7) are, respectively, S, G, E, T, E, D,  
 W--> 46 and T.  
 48 <220> FEATURE:  
 49 <221> NAME/KEY: MISC\_FEATURE  
 50 <222> LOCATION: (12)..(28) / /  
 51 <223> OTHER INFORMATION: Xaa(19) is C, G, P; Xaa(25) is A, P; Xaa(26) is P, A; Xaa(28) is  
 52 R or absent, provided that Xaa(25) and Xaa(26) are taken together  
 53 to form a sequence selected from the group consisting of AP and  
 54 PA.  
 56 <400> SEQUENCE: 1  
 W--> 58 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Val Val Gly Leu



59 1

5

10

15

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457D

DATE: 08/11/2004

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt

Output Set: N:\CRF4\08112004\I647457D.raw

62 Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Xaa Cys Xaa  
 63           20               25  
 66 <210> SEQ ID NO: 2  
 67 <211> LENGTH: 28  
 68 <212> TYPE: PRT  
 69 <213> ORGANISM: Unknown  
 71 <220> FEATURE:  
 72 <223> OTHER INFORMATION: being the immunologically active epitope  
 74 <400> SEQUENCE: 2  
 76 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu  
 77 1           5               10               15  
 80 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg  
 81           20               25  
 84 <210> SEQ ID NO: 3  
 85 <211> LENGTH: 16  
 86 <212> TYPE: PRT  
 87 <213> ORGANISM: Unknown  
 89 <220> FEATURE:  
 90 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.  
 93 <400> SEQUENCE: 3  
 95 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys  
 96 1           5               10               15  
 99 <210> SEQ ID NO: 4  
 100 <211> LENGTH: 20  
 101 <212> TYPE: PRT  
 102 <213> ORGANISM: Unknown  
 104 <220> FEATURE:  
 105 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.  
 108 <400> SEQUENCE: 4  
 110 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly  
 111 1           5               10               15  
 114 Ala Pro Cys Arg  
 115           20  
 118 <210> SEQ ID NO: 5  
 119 <211> LENGTH: 19  
 120 <212> TYPE: PRT  
 121 <213> ORGANISM: Unknown  
 123 <220> FEATURE:  
 124 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients  
 127 <400> SEQUENCE: 5  
 129 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala  
 130 1           5               10               15  
 133 Pro Cys Arg  
 137 <210> SEQ ID NO: 6  
 138 <211> LENGTH: 18  
 139 <212> TYPE: PRT

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457D

DATE: 08/11/2004

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt  
 Output Set: N:\CRF4\08112004\I647457D.raw

140 &lt;213&gt; ORGANISM: Unknown

142 &lt;220&gt; FEATURE:

143 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

144 levels in body fluids of schizophrenic patients

146 &lt;400&gt; SEQUENCE: 6

148 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro

149 1 5 10 15

152 Cys Arg

156 &lt;210&gt; SEQ ID NO: 7

157 &lt;211&gt; LENGTH: 17

158 &lt;212&gt; TYPE: PRT

159 &lt;213&gt; ORGANISM: Unknown

161 &lt;220&gt; FEATURE:

162 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

163 levels in body fluids of schizophrenic patients

165 &lt;400&gt; SEQUENCE: 7

167 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys

168 1 5 10 15

171 Arg

175 &lt;210&gt; SEQ ID NO: 8

176 &lt;211&gt; LENGTH: 17

177 &lt;212&gt; TYPE: PRT

178 &lt;213&gt; ORGANISM: Unknown

180 &lt;220&gt; FEATURE:

181 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

182 levels in body fluids of schizophrenic patients

184 &lt;400&gt; SEQUENCE: 8

186 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys

187 1 5 10 15

190 Arg

194 &lt;210&gt; SEQ ID NO: 9

195 &lt;211&gt; LENGTH: 17

196 &lt;212&gt; TYPE: PRT

197 &lt;213&gt; ORGANISM: Unknown

199 &lt;220&gt; FEATURE:

200 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

201 levels in body fluids of schizophrenic patients

203 &lt;400&gt; SEQUENCE: 9

205 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys

206 1 5 10 15

209 Arg

213 &lt;210&gt; SEQ ID NO: 10

214 &lt;211&gt; LENGTH: 20

215 &lt;212&gt; TYPE: PRT

216 &lt;213&gt; ORGANISM: Unknown

218 &lt;220&gt; FEATURE:

219 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

220 levels in body fluids of schizophrenic patients

222 <400> SEQUENCE: 10

## RAW SEQUENCE LISTING

DATE: 08/11/2004

PATENT APPLICATION: US/09/647,457D

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt

Output Set: N:\CRF4\08112004\I647457D.raw

224 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu  
 225 1 5 10 15  
 228 Cys Thr Gly Gln  
 229 20  
 232 <210> SEQ ID NO: 11  
 233 <211> LENGTH: 16  
 234 <212> TYPE: PRT  
 235 <213> ORGANISM: Unknown  
 237 <220> FEATURE:  
 238 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients  
 241 <400> SEQUENCE: 11  
 243 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg  
 244 1 5 10 15  
 247 <210> SEQ ID NO: 12  
 248 <211> LENGTH: 12  
 249 <212> TYPE: PRT  
 250 <213> ORGANISM: Unknown  
 252 <220> FEATURE:  
 253 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients  
 256 <400> SEQUENCE: 12  
 258 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg  
 259 1 5 10  
 262 <210> SEQ ID NO: 13  
 263 <211> LENGTH: 16  
 264 <212> TYPE: PRT  
 265 <213> ORGANISM: Unknown  
 267 <220> FEATURE:  
 268 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients  
 271 <400> SEQUENCE: 13  
 273 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys  
 274 1 5 10 15  
 277 <210> SEQ ID NO: 14  
 278 <211> LENGTH: 15  
 279 <212> TYPE: PRT  
 280 <213> ORGANISM: Unknown  
 282 <220> FEATURE:  
 283 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients  
 286 <400> SEQUENCE: 14  
 288 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro  
 289 1 5 10 15  
 292 <210> SEQ ID NO: 15  
 293 <211> LENGTH: 16  
 294 <212> TYPE: PRT  
 295 <213> ORGANISM: Unknown  
 297 <220> FEATURE:

## RAW SEQUENCE LISTING

DATE: 08/11/2004

PATENT APPLICATION: US/09/647,457D

TIME: 16:12:08

Input Set : A:\1276302-3corrected.ST25.txt  
Output Set: N:\CRF4\08112004\I647457D.raw

298 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients  
299  
301 <400> SEQUENCE: 15  
303 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys  
304 1 5 10 15

RAW SEQUENCE LISTING ERROR SUMMARY                    DATE: 08/11/2004  
PATENT APPLICATION: US/09/647,457D                    TIME: 16:12:09

Input Set : A:\1276302-3corrected.ST25.txt  
Output Set: N:\CRF4\08112004\I647457D.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28

**VERIFICATION SUMMARY** DATE: 08/11/2004  
PATENT APPLICATION: US/09/647,457D TIME: 16:12:09

Input Set : A:\1276302-3corrected.ST25.txt  
Output Set: N:\CRF4\08112004\I647457D.raw

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:38 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:39 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:40 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:41 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:42 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:43 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:44 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:45 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:46 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:58 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0  
M:341 Repeated in SeqNo=1